Chimeric antigen receptor (CAR) T cell therapy is an arising and extremely promising cellular immunotherapy approach to treat cancer. This innovative approach takes advantage of the characteristics of T cells, which are a key component of our immune system. These T cells, hundreds of billions of which circulate through our bodies at any given time, are capable of detecting and destroying cells that have been damaged, infected with viruses, or malignant.
Cancer is the second leading cause of death globally, accounting for an estimated 9.6 million deaths, or one in every six deaths. The burden of cancer continues to grow globally, exerting tremendous physical, emotional, and financial strain on individuals, families, communities as well as healthcare systems.
2020 has tabled many unforeseen challenges as well as opportunities to the Life Science division, most notably of course, with the world population relying on services and solutions provided mostly by biotech and pharmaceutics enterprises. Nonetheless, along with the necessity of being skilled and prepared for facing new versions of the COVID 19, a demand for safer drugs, more liability, and greater value from the life science industry is heightening.